Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376090 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00376090 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 48 participants.
The verdict
NCT00376090, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MVA-CMDR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376090
The ClinicalTrials.gov registry entry for NCT00376090 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00376090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376090 about?
NCT00376090 is a clinical study titled "Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults". The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.
What is the current status of trial NCT00376090?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00376090?
The interventions under investigation include: Placebo (BIOLOGICAL), MVA-CMDR (BIOLOGICAL).
Who is sponsoring clinical trial NCT00376090?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.